Supernus beats Q3 2026 estimates and raises full-year revenue guidance
FROM THE WIRE · FINANCE.YAHOO.COM
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company's…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRevenue and adjusted EPS above expectations plus a higher guidance can support the stock of this specialty pharma company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 revenue rose 18.1% year on year to $226.8 million, above analysts' estimates of $218.4 million.
- 02Adjusted EPS of $0.88 beat analysts' estimates of $0.49.
- 03Full-year revenue guidance was raised to $887.5 million at the midpoint from $875 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets